Relapsed diffuse large B-cell lymphoma

Studies that examine treatment options other than stem cell transplants for patients with relapsed DLBC or aggressive NHL.

The NHL Cyberfamily group

The website for information about non-Hodgkin's lymphoma. To join our on-line support group click button below.


Click here to visit our inspiration page. Here you'll find poems to comfort the soul, caregiver tips and some funny things too.

Research Library

Our research library page contains ASH abstracts, ASCO abstracts and other links to the latest innovations and research into lymphoma.

Treating non-Hodgkin's Lymphoma

Find information about the standard treatments, latest innovations in treatment and more

get in touch

Relapsed DLBC treatment options

As a general rule patients who have diffuse large B-cell lymphoma who relapse after initial treatment will be offered an autologous stem cell transplant as the preferred treatment.  However not every patient is able, or willing to undergo a stem cell transplant.

There is no single treatment alternative to SCT that is universally accepted as the "best" option for everyone. Therefore on this page we will try to give you a list of treatment options that are being used for relapsed DLBC, and other aggressive forms of NHL. Please be sure to discuss them with your doctor if you find yourself in this situation.

  1. Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  2. Rituximab, Gemcitabine, Cisplatin and Methylprednisolone (R-GEM-P) is an Effective Regimen in Relapsed Diffuse Large B-cell Lymphoma.

  3. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma

  4. Efficacy, safety, and cost efficiency of rituximab, gemcitabine, dexamethasone, and oxaliplatin (RGDOx) in B-cell NHL

  5. Treatment with cyclophosphamide, vindesine, cytarabine, dexamethasone, and bleomycin in patients with relapsed/refractory diffuse large B cell lymphoma.

  6. A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma

  7. A Phase II Trial of Alemtuzumab (Campath) with DA-EPOCH-R in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma
  8. The Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), Has Preferential Activity in the ABC Subtype of Relapsed/Refractory De Novo Diffuse Large B-Cell Lymphoma (DLBCL): Interim Results of a Multicenter, Open-Label, Phase 2 Study

  9. Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-risk CD20+ NHL not eligible for standard ASCT: Five-year results

  10. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.

  11. Higher response to lenalidomide in relapsed/refractory diffuse large b-cell lymphoma in nongerminal center b-cell–like than in germinal center b-cell–like phenotype

  12. Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas 

  13. Phase II Trial Shows Zevalin(R) Effective Therapy for Relapsed/Refractory Patients With Diffuse Large B-Cell Lymphoma

  14. SGN-40 (Anti-huCD40 mAb) Monotherapy Induces Durable Objective Responses in Patients with Relapsed Aggressive Non-Hodgkins Lymphoma: Evidence of Antitumor Activity from a Phase I Study

  15. Results of a Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone in Patients with Relapsed Aggressive Non-Hodgkins Lymphoma

  16. A Phase II Study of Sepantronium Bromide (YM155) Plus Rituximab in Previously Treated Subjects with Aggressive CD20-Positive B Cell Non-Hodgkin’s Lymphoma Who Are Ineligible for or Have Previously Received an Autologous Stem Cell Transplant - Stage I Results

  17. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma


slide up button